Stem cell therapy repairs injured peripheral nerves in animal models
Gingiva-derived mesenchymal stem cells were used to surgically repair injured peripheral nerves, showing potential for new therapies.
List view / Grid view
Gingiva-derived mesenchymal stem cells were used to surgically repair injured peripheral nerves, showing potential for new therapies.
A CRISPR screening tool identified a new target for acute myeloid leukaemia with fewer side effects than current approaches.
A new study found that the RNA RN7SL1 can activate T cells to seek out cancer cells, potentially improving cellular treatments.
Researchers identified the inhibitor JQ1 as a potential drug to improve immune response to CAR T-cell therapies in leukaemia patients.
New findings from collaborative research in the United States have identified a promising new treatment avenue for type 2 diabetes patients centring on the activity of the amino acid, GABA.
A new mRNA vaccine based on the malaria circumsporozoite protein was shown to elicit a robust immune response in mice.
A study using stem cells has revealed that DCM-causing mutations in LMNA disrupt the organisation of DNA in the nucleus of heart muscle cells.
Scientists have found that a new knee injection using nanomedicine could prevent the effects of osteoarthritis.
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
Researchers have identified an enzyme required for the formation of sperm and chromosomal pairing, which they say could be a target to treat male infertility.
An mRNA vaccine has been developed which has elicited strong immune responses in mice in the presence of maternal antibodies.
New research goes against the paradigm of HIV control that focuses on killing off infected cells and supports a model in which viral suppression could possibly serve as a cure.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
An animal model to test HIV infection in infants could lead to biomarkers that predict viral rebound after ART interruption.
A study has found that signals from interferons can be blocked, allowing the immune system to attack tumours which provides a potential target.